Amarin received a notice of allowance from the U.S. Patent and Trademark Office for an application covering a stable pharmaceutical composition of AMR101, a treatment candidate for high triglyceride level, with at least 95% eicosapentaenoic acid. Amarin, which has more than 25 pending patent applications in the U.S., aims to protect "the commercial potential of AMR101 to 2030 and beyond," Chairman and CEO Joseph Zakrzewski said.
Anesthesia may affect lipids in cells' outer membranes, changing nerve cell communication, according to the National Institute of Standards and Technology. The study may show why inhaling anesthetics causes unconsciousness. NIST scientists used X-ray diffraction to study how cell membranes reacted to an inhaled anesthetic as well as a chemical that does not cause unconsciousness.
Netherlands-based life sciences company Royal DSM has bought the food enzymes and oilseed-processing business of Verenium for $37 million. The deal is expected to fortify DSM's nutrition, food ingredients and enzymes units.
Amarin intends to submit cholesterol drug candidate AMR101 for FDA approval by the end of next month. The compound proved safe and well-tolerated among clinical-trial patients with a high level of triglycerides, Amarin said.
Amarin plans to file by the third quarter for FDA approval of AMR101, a treatment for patients with a high level of triglycerides. Amarin said data from an early-stage trial are sufficient to support a filing. "Our focus is to become the leader in the market for triglyceride-lowering drugs," CEO Joseph Zakrzewski said.